SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
暂无分享,去创建一个
A. Tefferi | M. Patnaik | T. Lasho | R. Ketterling | A. Pardanani | C. Hanson | C. Finke | T. Jimma | Thitina Jimma
[1] M. Gönen,et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. , 2012, Blood.
[2] A. Tefferi,et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.
[3] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[4] Claude Preudhomme,et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.
[5] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[6] Franco Locatelli,et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. , 2012, Blood.
[7] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[8] A. Tefferi,et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F , 2011, Leukemia.
[9] A. Tefferi,et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. , 2012, Mayo Clinic proceedings.
[10] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[11] P. Guglielmelli,et al. Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis , 2011 .
[12] P. Guglielmelli,et al. EZH2 mutational status predicts poor survival in myelofibrosis. , 2011, Blood.
[13] A. Tefferi,et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. , 2011, Blood.
[14] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[15] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[16] P. Guglielmelli,et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients , 2011, Leukemia.
[17] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Gilliland,et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis , 2010, Leukemia.
[19] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[20] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[21] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[22] R. Mesa,et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.
[23] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.